Pharma Tech

Andelyn Biosciences to develop GM2 gangliosidosis therapy

Aug 19, 2026, 9:04 AM

Read Full Article → Andelyn Biosciences to develop GM2 gangliosidosis therapy

Translate article text

Choose a language and wait for the translated text.

Andelyn Biosciences is set to develop and manufacture a gene therapy known as AAV9-GM2, for Queen’s University to treat GM2 gangliosidoses, including Tay-Sachs and Sandhoff diseases.